A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s ...

The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

Despite rehiring hundreds of FDA, CDC and NIH employees, the Department of Health and Human Services is still a skeleton of ...

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

In an open letter addressing the Trump administration's proposed budget cuts to HHS, the executives urged Congress to ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Changing how biopharmas package their products, how regulators review new drugs and how mutated genes are fixed could make ...